|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||31.82 - 34.19|
|52 Week Range||31.50 - 68.05|
|Beta (3Y Monthly)||4.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.92|
Investors need to pay close attention to Global Blood Therapeutics (GBT) stock based on the movements in the options market lately.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
One of the first tenants in The Cove at Oyster Point is taking the last building in the South San Francisco development as rents in the region hit new highs.
NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans ...
On a per-share basis, the South San Francisco, California-based company said it had a loss of 83 cents. The results surpassed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks ...
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported business progress and financial results for the third quarter.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 1, 2018, the compensation.
NEW YORK , Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union ...
Company to Present Three Oral Presentations, Including Results Beyond 12 Weeks from Part A of the HOPE Study Company to Host Investor Webcast on Monday, December 3 SOUTH SAN.
Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €581.4M for the first nine months of the 2018 financial year, down 3.3% due to a highly unfavourable currency effect representing €32.9M. At constant exchange rates, the Group's revenue increased 2.1% to €614.3M, identical to the dynamics observed in the first half of the year. In Europe, sales were down 7.8% at constant exchange rates.
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on October 1, 2018, the compensation committee of the.
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that three abstracts related to its sickle cell disease (SCD).
NEW YORK, Sept. 27, 2018-- Attorney Advertising---- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Global Blood Therapeutics, Inc.. Such investors are encouraged ...
NEW YORK, Sept. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018-- Global Blood Therapeutics, Inc. today announced that it will present at the 2018 Cantor Global Healthcare Conference in New York City on Tuesday, October 2 ...
Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, has reported its consolidated half-year results, following the limited review by its auditors. This slight decline is mainly attributable to Optiray® on the CT/Cath Lab segment.
NEW YORK, Sept. 24, 2018 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Alnylam Pharmaceuticals,.
NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: ...
Are you looking for a post-summer portfolio boost? Look no further. Investment firm Oppenheimer has released a bullish report highlighting its latest Top Stock Picks for September 2018. "These are the most timely stocks in the opinion of our research analysts" stated the firm. "Each analyst was asked to contribute the one idea they considered to outperform over the next 12 months, based on their view of the company's fundamentals in the context of current market conditions." The report lists 30 top stocks. But here I focus on the seven stocks that truly stand out from the crowd. I used TipRanks' market data to cherry-pick the report's best stocks. These are the the stocks which boast a "strong buy" consensus rating from the Street. This is based on all the ratings each stock has received over the last three months. That way we have the added reassurance of knowing that these stocks score big across the board.Let's take a closer look at these hot shots now: SEE ALSO FROM KIPLINGER: 12 Top Stock Picks to Shield Your Portfolio
Investors need to pay close attention to Global Blood (GBT) stock based on the movements in the options market lately.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. (“Global Blood” or “the Company”) (NASDAQ: GBT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Stat published an article about Global Blood, claiming that there are “important risks that investors might be glossing over” about the likelihood of Global Blood’s new drug for sickle cell disease, voxelotor, being approved by the FDA.
NEW YORK, NY / ACCESSWIRE / September 14, 2018 / Wall Street closed up on Thursday as tech shares rallied and trade tensions eased on the hopes of a fresh round of trade talks, that could potentially take ...
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Global Blood Therapeutics, Inc. resulting from allegations that Global Blood may have issued materially misleading business information to the investing public.
NEW YORK, Sept. 13, 2018-- Bragar Eagel & Squire, P.C. is investigating potential claims against Global Blood Therapeutics, Inc.. Our investigation concerns whether Global Blood has violated the federal ...